Inovio announces publication of phase 1 data from its covid-19 dna vaccine candidate, ino-4800 in the lancet's eclinicalmedicine

Plymouth meeting, pa., dec. 24, 2020 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed phase 1...
INO Ratings Summary
INO Quant Ranking